{
  "source": "PA-Notification-Pomalyst.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1077-14\nProgram Prior Authorization/Notification\nMedication Pomalyst® (pomalidomide)\nP&T Approval Date 2/2013, 7/2013, 5/2014, 5/2015, 5/2016, 5/2017, 5/2018, 5/2019,\n5/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nPomalyst® (pomalidomide) is a thalidomide analogue indicated for the treatment of adult\npatients, in combination with dexamethasone, for patients with multiple myeloma who have\nreceived at least two prior therapies including Revlimid® (lenalidomide) and a proteasome\ninhibitor [e.g., Velcade® (bortezomib)] and have demonstrated disease progression on or\nwithin 60 days of completion of the last therapy. Pomalyst is also indicated for adult patients\nwith AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy\n(HAART) or in patients with KS who are HIV-negative.1\nThe National Comprehensive Cancer Network (NCCN) also recommends use of Pomalyst for\nthe treatment of relapsed/refractory systemic light chain amyloidosis in combination with\ndexamethasone and for the treatment of primary central nervous system (CNS) lymphoma.\nAdditionally, Pomalyst is recommended in NCCN for treatment of multiple myeloma in\ncombination of dexamethasone after receiving only one prior line of therapy or for induction\ntherapy for the management of POEMS.2\nDue to embryo-fetal risk (pregnancy category X) associated with Pomalyst; it is available only\nthrough the Pomalyst Risk Evaluation and Mitigation Strategy (REMS) Program. Prescribers\nand pharmacies must be certified with the Pomalyst REMS Program by enrolling and\ncomplying with the REMS requirements. Patients must sign a Patient-Physician agreement\nform and comply with the REMS requirements. Specifically, female patients who are not\npregnant but can become pregnant must comply with the pregnancy testing and contraception\nrequirements and males must comply with contraception requirements. Phar",
    "ifically, female patients who are not\npregnant but can become pregnant must comply with the pregnancy testing and contraception\nrequirements and males must comply with contraception requirements. Pharmacies must only\ndispense to patients who are authorized to receive the drug and must comply with REMS\nrequirements. Additional information may be found at: https://www.pomalystrems.com/.3\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n© 2025 UnitedHealthcare Services, Inc.\n1\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Pomalyst will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Multiple Myeloma\n1. Initial Authorization\na. Pomalyst will be approved based on both of the following criteria:\n(1) Diagnosis of multiple myeloma\n-AND-\n(2) One of the following:\n(a) History of failure, contraindication, or intolerance to one of the following:\ni. Immunomodulatory agent [e.g., Revlimid (lenalidomide)]\nii. Proteasome inhibitor [e.g.,Velcade (bortezomib)]\niii. Anti CD-38 therapy [e.g., Darzalex (daratumumab), Sarclisa\n(isatuximab)]\n-OR-\n(b) Induction therapy for the management of POEMS (polyneuropathy,\norganomegaly, endocrinopathy, monoclonal protein, skin changes)\nsyndrome\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Pomalyst will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Pomalyst\ntherapy\nAuthorization will be issued for 12 months.\nC. Systemic Light Chain ",
    "l be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Pomalyst\ntherapy\nAuthorization will be issued for 12 months.\nC. Systemic Light Chain Amyloidosis\n1. Initial Authorization\n© 2025 UnitedHealthcare Services, Inc.\n2\na. Pomalyst will be approved based on both of the following criteria:\n(1) Diagnosis of systemic light chain amyloidosis\n-AND-\n(2) Used in combination with dexamethasone\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Pomalyst will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Pomalyst\ntherapy\nAuthorization will be issued for 12 months.\nD. Kaposi Sarcoma\n1. Initial Authorization\na. Pomalyst will be approved based on one of the following criteria:\n(1) Diagnosis of HIV-negative Kaposi Sarcoma\n-OR-\n(2) Both of the following:\n(a) Diagnosis of AIDS-related Kaposi Sarcoma\n-AND-\n(b) Patient is currently being treated with antiretroviral therapy (ART)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Pomalyst will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Pomalyst\ntherapy\nAuthorization will be issued for 12 months.\nE. Primary CNS Lymphoma\n© 2025 UnitedHealthcare Services, Inc.\n3\n1. Initial Authorization\na. Pomalyst will be approved based on both of the following criteria:\n(1) Diagnosis of primary CNS lymphoma\n-AND-\n(2) One of the following:\n(a) Used as second-line or a subsequent therapy\n(b) Use as induction therapy if patient is unsuitable for or intolerant to high-\ndose methotrexate\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Pomalyst will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Pomalyst\ntherapy\nAuthorization will be issued for 12 months.\nF. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by T",
    "dence of progressive disease while on Pomalyst\ntherapy\nAuthorization will be issued for 12 months.\nF. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Pomalyst [package insert]. Summit, NJ: Celgene Corporation; February 2025.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed April 9, 2025.\n© 2025 UnitedHealthcare Services, Inc.\n4\n3. Pomalyst REMS®. Available at https://www.pomalystrems.com/. Accessed April 9, 2025.\nProgram Prior Authorization/Notification - Pomalyst (pomalidomide)\nChange Control\n5/2014 Annual review. Added coverage for criteria for systemic light chain\namyloidosis per NCCN.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n5/2015 Updated background, coverage criteria and references. Increased\nauthorization from 8 months to 12 months.\n5/2016 Annual review. Added dexamethasone to background. Added\nproteasome inhibitor to Velcade in background and coverage criteria.\nUpdated references.\n5/2017 Annual review. Changed member to patient in coverage criteria.\nUpdated formatting and references.\n5/2018 Annual review. Added coverage criteria for AIDS-Related Kaposi\nSarcoma per NCCN. Up",
    "ces.\n5/2017 Annual review. Changed member to patient in coverage criteria.\nUpdated formatting and references.\n5/2018 Annual review. Added coverage criteria for AIDS-Related Kaposi\nSarcoma per NCCN. Updated references.\n5/2019 Annual review. Added coverage criteria for primary CNS lymphoma\nper NCCN. Updated references.\n5/2020 Annual review. No changes to coverage criteria. Updated references.\n5/2021 Annual review. Added coverage criteria for HIV-negative Kaposi\nSarcoma per package insert. Updated references.\n5/2022 Annual review. Added NCCN Recommended Regimens criteria.\nUpdated references.\n5/2023 Annual review with no changes to coverage criteria. Updated\nbackground and references. Added state mandate footnote.\n5/2024 Annual review. Updated criteria for multiple myeloma and kaposi\nsarcoma. Updated background and references.\n5/2025 Annual review. Updated criteria for multiple myeloma and primary\nCNS lymphoma based on NCCN recommendation. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n5"
  ]
}